Differences in the Fecal Metabolome of Autoimmune Pancreatitis Patients
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Vladyslav Dovhalyuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry - BMC, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Feces, Autoimmune Pancreatitis, Metabolome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission, Vetenskapsrådet, Cancerfonden.
Abstract (Originalsprache)
Background
Chronic pancreatitis is a risk factor for pancreatic cancer. Autoimmune pancreatitis is a unique form of chronic pancreatitis that is primarily characterized by its immune mediate etiology, clinically resembling pancreatic cancer, yet uniquely responsive to steroid treatment.
Objective
Early and accurate diagnosis of autoimmune pancreatitis is vital for effective treatment and patient prognosis, for which new diagnostic tools are urgently required. Gut microbiota dysbiosis has been identified to correlate with the development of pancreatic diseases, which provides new opportunities for the discovery of disease biomarkers.
Methods
We utilized a mass spectrometric global metabolomics investigation of patient autoimmune pancreatitis and chronic pancreatitis fecal samples, investigating microbiome, dietary and human metabolism.
Results
We discovered a series of newly identified metabolic signatures between both patient groups including enterolactone, 4‐guanidinobutanoic acid, and methylthioadenosine sulfoxide. Additionally, the analysis revealed significant differences in several metabolic pathways such as fatty acids, alkaloids, amino acids and peptides.
Conclusion
Our observations provide novel insights into important metabolic human pathways and microbiome‐derived metabolites to distinguish autoimmune pancreatitis from chronic pancreatitis. These findings reveal systemic metabolic responses and the identified metabolites may be developed into potential biomarkers for future diagnosis to distinguish between autoimmune pancreatitis and chronic pancreatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry - BMC, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- Department of Gastroenterology, Clinic of Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia.
- Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
- Department for Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.
ORCID-Profile: Vladyslav Dovhalyuk, Miroslav Vujasinovic, J-Matthias Löhr, Daniel Globisch
Förderung
- European Commission
- Vetenskapsrådet
- Cancerfonden
Zitieren
APA
Dovhalyuk, V., Yang, F., Nikolic, S., Vujasinovic, M., Löhr, J. M., & Globisch, D. (2025). Differences in the Fecal Metabolome of Autoimmune Pancreatitis Patients. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70025
Vancouver
Dovhalyuk V, Yang F, Nikolic S, Vujasinovic M, Löhr JM, Globisch D. Differences in the Fecal Metabolome of Autoimmune Pancreatitis Patients. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.70025
BibTeX
@article{Dovhalyuk2025,
author = {Dovhalyuk, Vladyslav and Yang, Fan and Nikolic, Sara and Vujasinovic, Miroslav and Löhr, J-Matthias and Globisch, Daniel},
title = {Differences in the Fecal Metabolome of Autoimmune Pancreatitis Patients},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.70025}
}
EUVIMED